• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Mainz Biomed N.V.

    6/5/25 5:00:14 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYNZ alert in real time by email
    6-K 1 ea0244743-6k_mainz.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

     

    Commission File No. 001-41010

     

    MAINZ BIOMED N.V.

    (Translation of registrant’s name into English)

     

    Robert Koch Strasse 50
    55129 Mainz
    Germany

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    Other Events

     

    Results of Annual General Meeting of Shareholders

     

    On June 2, 2025, Mainz Biomed N.V. (the “Company”) held an Annual General Meeting of Shareholders (the “Annual General Meeting”). All proposals brought before the holders of the Company’s ordinary shares at such meeting were approved. Minutes announcing the results of the Annual General Meeting are attached hereto as Exhibit 99.1.The final results of each of the agenda items submitted to a vote by the shareholders are as follows:

     

    At the Annual General Meeting, a total of 182,883 shares (or 5.31%) of the Company’s issued and outstanding shares of record held as of May 5, 2025, the record date for the Annual General Meeting, were present either in person or by proxy. At the Annual General Meeting, the following proposals were voted on and approved:

     

      1. Adoption of the statutory annual accounts for the financial year ended 31 December 2024:

     

    Votes For   Votes Against   Abstentions 
     150,635    30,417    1,831 

      

      2. Discharge from liability of the directors for their management and supervision during the financial year ended 31 December 2024:

     

    Votes For   Votes Against   Abstentions 
     115,880    64,373    2,630 

     

      3. Amendment of the articles of association and authorisation of CMS Derks Star Busman N.V., to have the deed of amendment of articles of association executed:

     

    Votes For   Votes Against   Abstentions 
     138,666    38,752    5,465 

     

      4. Extension of the authorisation of the board to acquire ordinary shares or depositary receipts thereof:

     

    Votes For   Votes Against   Abstentions 
     137,160    38,212    7,511 

     

      5. Extension of the authorisation of the board to acquire preferred shares or depositary receipts thereof:

     

    Votes For   Votes Against   Abstentions 
     131,759    38,433    12,691 

     

      6. Cancellation of ordinary shares held by the Company:

     

    Votes For   Votes Against   Abstentions 
     128,527    49,017    5,339 

     

      7. Reappointment of Mr. G. Bächler as executive director:

     

    Votes For   Votes Against   Abstentions 
     142,104    37,709    3,070 

     

    1

     

     

      8. Reappointment of Mr. H.J. Hekland as non-executive director:

     

    Votes For   Votes Against   Abstentions 
     138,833    41,417    2,839 

     

      9. Reappointment of Mr. G.J. Tibbitts as non-executive director:

     

    Votes For   Votes Against   Abstentions 
     138,833    41,207    2,843 

     

      10. Reappointment of Dr. H. Dreismann as non-executive director:

     

    Votes For   Votes Against   Abstentions 
     144,010    35,936    2,937 

     

      11. Approval of the 2025 Omnibus Incentive Plan:

     

    Votes For   Votes Against   Abstentions 
     131,125    49,463    2,295 

     

      12. Amendment of the remuneration policy and confirmation of awards granted to directors:

     

    Votes For   Votes Against   Abstentions 
     119,445    59,631    3,807 

     

      13. Assignment of Kreston Lentink Audit B.V. as Dutch auditor and authorisation of the board to assign a US auditor at its discretion for the financial year ending 31 December 2025:

     

    Votes For   Votes Against   Abstentions 
     154,459    27,070    1,354 

     

    This current report on Form 6-K and the exhibit hereto are hereby incorporated by reference into our registration statement on Form F-3 (no. 333-269091) as well as our registration statement on Form S-8 (no. 333-273203).

     

    Exhibit No.   Exhibit
    99.1   Board Minutes Regarding the Annual General Meeting dated June 3, 2025

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 5, 2025 By: /s/ William J. Caragol
      Name:  William J. Caragol
      Title Chief Financial Officer

     

    3

    Get the next $MYNZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYNZ

    DatePrice TargetRatingAnalyst
    2/14/2025$14.00Buy
    Maxim Group
    11/25/2024Buy → Neutral
    H.C. Wainwright
    11/21/2023Overweight → Neutral
    Cantor Fitzgerald
    6/21/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $MYNZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mainz Biomed to Attend 2025 Maxim Growth Summit

    BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23, 2025, at The Hard Rock Hotel NYC. The prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with C

    10/15/25 9:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

    Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening test for the early detection of pancreatic cancer, initiated earlier this year. The study confirmed the strong clinical accuracy and utility of licensed proprietary biomarkers from Liquid Biosciences for developing an innovative screening test for pancreatic cancer. Researchers evaluated 18 licensed biomarkers across multiple candidate panels to streamline assay complexity. The leading panel achieved 100% sensitivity and 95% specifi

    10/8/25 9:00:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

    BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection

    9/30/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Mainz Biomed B.V. with a new price target

    Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

    2/14/25 8:10:14 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed B.V. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

    11/25/24 7:48:30 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed B.V. downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

    11/21/23 7:33:52 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    SEC Filings

    View All

    SEC Form 6-K filed by Mainz Biomed N.V.

    6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

    10/3/25 5:25:52 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Mainz Biomed N.V.

    424B5 - MAINZ BIOMED N.V. (0001874252) (Filer)

    10/3/25 5:25:29 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Mainz Biomed N.V.

    424B3 - MAINZ BIOMED N.V. (0001874252) (Filer)

    10/3/25 5:25:00 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

    BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection

    9/30/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Enters into Technology Partnership with EDX Medical Group

    BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

    4/29/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

    BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

    9/18/24 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mainz Biomed N.V.

    SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

    10/7/24 4:47:27 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Mainz Biomed N.V. (Amendment)

    SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

    2/13/24 2:39:04 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Mainz Biomed N.V.

    SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

    3/1/23 6:38:43 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Financials

    Live finance-specific insights

    View All

    Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

    Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

    2/21/23 3:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

    Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

    1/5/22 3:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care